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ability to ensure continous availability of energy despite highly variable
supplies in the environment is a major determinant of the survival of all
species. In higher organisms, including mammals, the capacity to effi-
ciently store excess energy as triglycerides in adipocytes, from which
stored energy could be rapidly released for use at other sites, was
developed. To orchestrate the processes of energy storage and release,
highly integrated systems operating on several physiological levels have
evolved. The adipocyte is no longer considered a passive bystander,
because fat cells actively secrete many members of the cytokine family,
such as leptin, tumor necrosis factor-a, and interleukin-6, among other
cytokine signals, which influence peripheral fuel storage, mobilization,
and combustion, as well as energy homeostasis. The existence of a
network of adipose tissue signaling pathways, arranged in a hierarchical
fashion, constitutes a metabolic repertoire that enables the organism to
adapt to a wide range of different metabolic challenges, such as starva-
tion, stress, infection, and short periods of gross energy excess.
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OVERVIEW
Unraveling the diverse hormonal and neuroendo-
crine systems that regulate energy balance and body
fat has been a long-standing challenge in biology, with
obesity as an increasingly important public health fo-
cus (12). Adipose tissue is the body’s largest energy
reservoir. For example, an adult with 15 kg of body fat
has .460 MJ (110,000 kcal) of lipid fuel stores, which
could provide 8.37 MJ (2,000 kcal) daily for ;2 mo (75,
129). The primary role of adipocytes is to store triacyl-
glycerol during periods of caloric excess and to mobilize
this reserve when expenditure exceeds intake. Mature
adipocytes are uniquely equipped to perform these
functions. They possess the full complement of en-
zymes and regulatory proteins needed to carry out both
lipolysis and de novo lipogenesis. In fat cells, the reg-
ulation of these processes is exquisitely responsive to
hormones, cytokines, and other factors that are in-
volved in energy metabolism (87). The ability to carry
out these functions is acquired during embryonic de-
velopment in preparation for the postnatal period,
when an adipose energy reserve becomes necessary.
Major expansion of the white adipocyte population is
delayed until shortly after birth, although preadipo-
cytes first appear late in embryonic life (22).
The present review will focus on the evidence for the
synthesis and secretion by white adipocytes of endo-
crine, paracrine, and autocrine signals implicated in
energy balance regulation, with special reference to
cytokines. The interactions between these adipose tis-
sue-derived mediators and other neuroendocrine path-
ways will be examined. Furthermore, the metabolic
alterations in adipose tissue signaling leading to obe-
sity and insulin resistance will be described.
WHITE ADIPOSE TISSUE SIGNALS
Adipocytes, which vary enormously in size (20–200
mm in diameter), are embedded in a connective tissue
matrix and are uniquely adapted to store and release
energy. Surplus energy is assimilated by fat cells and
stored as triglycerides in lipid droplets. To accommo-
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date the lipids, adipocytes are capable of changing
their diameter 20-fold and their volumes by several
thousandfold. Because ;90% of the cell volume is a
lipid droplet, the nucleus and the thin cytoplasmic rim
are pushed to the periphery of the adipocytes. White
adipose tissue is actively involved in cell function reg-
ulation through a complex network of endocrine, para-
crine, and autocrine signals that influence the response
of many tissues, including hypothalamus, pancreas,
liver, skeletal muscle, kidneys, endothelium, and im-
mune system, among others. Until recently, the adipo-
cyte has been considered to be only a passive tissue for
the storage of excess energy in the form of fat (37).
However, there is now compelling evidence that adipo-
cytes act as endocrine secretory cells (37, 143). It has
been shown that several hormones, growth factors, and
cytokines are actually expressed in white adipose tis-
sue (Tables 1 and 2). In a dynamic view of the adipo-
cyte, a wide range of signals emanates from white
adipose tissue, such as leptin, tumor necrosis factor-a
(TNF-a), interleukin-6 (IL-6), and their respective sol-
uble receptors. White adipose tissue also secretes im-
portant regulators of lipoprotein metabolism, like li-
poprotein lipase (LPL), apolipoprotein E (apoE), and
cholesteryl ester transfer protein (CETP). The increas-
ing number of products secreted by adipocytes also
includes angiotensinogen, plasminogen activator in-
hibitor-1 (PAI-1), tissue factor, and transforming
growth factor-b (TGF-b). Nitric oxide synthase (NOS)
has also been reported to be expressed in rat white
adipose tissue, indicating that adipocytes are a poten-
tial source of NO production (131). Recently, evidence
for an involvement of NO in both rat and human
lipolysis has been published (3, 48). Interestingly, lep-
tin immunolabeling of white adipocytes exhibits an
absolutely superimposable staining pattern to that of
inducible NOS (iNOS), as can be observed in histolog-
ical sections (Fig. 1 and 2). The role of insulin-like
growth factor I (IGF-I), glucocorticoids, and sex ste-
roids in adipose tissue proliferation, heterogeneity, and
distribution is beginning to be better understood. How-
ever, the influence of acylation-stimulating protein
(ASP), adipophilin, adipoQ, adipsin, monobutyrin, ag-
outi protein, and factors related to proinflammatory
and immune processes still remains to be fully eluci-
dated (14). These relationships show that white adi-
pose tissue lies at the heart of a network of autocrine,
paracrine, and endocrine signals (Fig. 3). Through the
existence of a network of local and systemic signals,
which interact with neuroendocrine regulators, adi-
pose tissue signaling pathways, arranged in a hierar-
chical fashion, constitute one of the voices of the body
that enable the organism to adapt to a range of differ-
ent metabolic challenges, such as starvation, stress,
and infection, as well as periods of gross energy excess.
ADIPOCYTE SECRETORY PRODUCTS AND THEIR
METABOLIC EFFECTS
Adipocytes produce a great number of factors that
serve as feedback signals to regulate adipose tisssue
metabolism. Undoubtedly, the development of sophis-
ticated molecular techniques has contributed to the
identification of many of the secretory products of ad-
ipose tissue.
Adipsin
Adipsin is a serine protease secreted by fat cells. It
was originally identified as a highly differentiation-
dependent gene in 3T3-L1 adipocytes (21). Expression
of adipsin is markedly downregulated in rodent obesi-
ties, probably as a consequence of increased concentra-
Table 1. Proteins secreted by adipose tissue to the bloodstream
Molecule Function/Effect Reference
Leptin Signals to the brain about body fat stores 44, 196
Regulation of appetite and energy expenditure
TNF-a Interferes with insulin receptor signaling and is a possible cause of the development of insulin
resistance in obesity
62, 65
IL-6 Implicated in host defense and in glucose and lipid metabolism 111
PAI-1 Potent inhibitor of the fibrinolytic system 146
Tissue factor Major cellular initiator of the coagulation cascade 41
Angiotensinogen Precursor of angiotensin II. Regulator of blood pressure and electrolyte homeostasis 76
Adipsin Possible link between the activation of the alternative complement pathway and adipose tissue
metabolism
19, 41
ASP Influences the rate of triacylglycerol synthesis in adipose tissue 41
Adipophilin May be a specific marker for lipid accumulation in the cells 59
AdipoQ/apM1/
Adiponectin/Acrp
May play a role in the pathogenesis of Familial Combined Hyperlipidemia and associated insulin
resistance
67
PGI2 and PGF2a Implicated in regulatory functions such as inflammation and blood clotting, ovulation,
menstruation, and acid secretion
111
TGFb Regulates a wide variety of biological responses, including proliferation, differentiation, apoptosis,
and development
154
IGF-I Stimulates proliferation of a wide variety of cells and mediates many of the effects of growth
hormone
18, 141
MIF Involved in proinflammatory processes and immunoregulation 134
TNF-a, tumor necrosis factor-a; IL-6, interleukin-6; PAI-1, plasminogen activator inhibitor-1; ASP, acylation-stimulating protein; Acrp,
adipocyte complement-related protein, or AdipoQ; apM1, adipose most abundant gene transcript 1; PGI2 and PGF2a, prostaglandins I2 and










Table 2. White adipocyte receptors
Receptor Main Effect of Receptor Activation on Adipocyte Metabolism Reference
Hormone-cytokine receptors
Leptin (OB-R) Stimulation of lipolysis 1, 6, 43, 195
Autocrine regulation of leptin expression
Insulin Inhibition of lipolysis and stimulation of lipogenesis 82
Induction of glucose uptake and oxidation
Stimulation of leptin expression
Glucagon Stimulation of lipolysis 73
IGF-I and -II Inhibition of lipolysis 162
Stimulation of glucose transport and oxidation
GH Induction of leptin and IGF-I expression 176
Stimulation of lipolysis
TSH Regulation of adipocyte differentiation 34
Regulation of lipolysis
Prostaglandin Strong antilypolitic effects (PGE2) 41
Modulation of preadipocyte differentiation (PGF2a and PGI2)
TNF-a Stimulation of lipolysis 56, 68
Regulation of leptin secretion
Potent inhibition of adipocyte differentiation
Involvement in development of insulin resistance
IL-6 LPL activity inhibition 111
Induction of lipolysis
Adenosine Inhibition of lipolysis 174
Gastrin/CCK-B Regulation of expression and secretion of leptin 41
GIP Fatty acid and triglyceride synthesis stimulation 187, 188
Amplification of insulin effects
GLP-1 Regulation of glycogen synthesis 29
Enhancement of insulin-stimulated glucose metabolism
NPY-Y1 Inhibition of lipolysis 31
Induction of leptin expression
ANP Oxidative glucose metabolism modulation (via NPR-A) 139
Clearance of ANP (via NPR-C)
Angiotensin II Increase of lipogenesis 76, 197
Stimulation of prostacyclin production by mature fat cells
Interaction with insulin in regulation of adipocyte metabolism
EGF Regulation of adipocyte differentiation 57, 141
Interference with the lipolytic effect of catecholamines
PDGF Regulation of adipocyte differentiation 41, 57
FGF Regulation of adipocyte differentiation 57, 115
TGFb Potent inhibition of adipocyte differentiation 137, 154
Catecholamine-nervous system receptors
b1, b2, b3, (b4?) Stimulation of lipolysis 91
Induction of thermogenesis
Reduction of leptin mRNA levels
a1 Induction of inositol phosphate production and PKC activation 91, 164
a2 Inhibition of lipolysis 91
Regulation of preadipocyte growth
nicotinic ? Stimulation of lipolysis 12, 22
muscarinic ? Inhibition of lipolysis 41
Nuclear receptors
PPARg Induction of adipocyte differentiation and insulin sensitivity 91, 192
RAR/RXR Regulation of adipocyte differentiation 177
T3 Stimulation of lipolysis 41, 111
Regulation of leptin secretion
Induction of adipocyte differentiation
Regulation of insulin effects
Glucocorticoids Stimulation of adipocyte differentiation 12, 141
Androgen Control of adipose tissue development (antiadipogenic signals) 27, 87, 100
Modulation of ob gene expression
Estrogen Control of adipose tissue development (proadipogenic signals) 12, 27, 87
Modulation of ob gene expression
Progesterone Regulation of fat metabolism and distribution 87, 117
Vitamin D Inhibition of adipocyte differentiation 79
Lipoprotein receptors
VLDL Binding and internalization of VLDL particles 163
Play a role in lipid accumulation
LDL Stimulation of cholesterol uptake 88
HDL Clearance and metabolism of HDL 135
OB-R, leptin receptors; GH, growth hormone; TSH, thyroid-stimulating hormone; LPL, lipoprotein lipase; CCK-B, cholecystokinin-B; GIP, gastric inhibitory
peptide; GLP-1, glucagon-like peptide-1; NPY-Y1, neuropeptide Y-Y1; ANP, atrial natriuretic peptide; NPR, neuropeptide receptor; EGF, PDGF, and FGF,
epidermal, platelet-derived, and fibroblast growth factors, respectively; PKC, protein kinase C; PPARg, peroxisome proliferator-activated receptor-g; RAR and










tions of insulin and glucocorticoids (21). Sequence com-
parison revealed that both murine adipsin and human
adipsin were identical to complement D (165), the
initial and rate-limiting enzyme in the alternative
complement pathway. It was shown that fat cells syn-
thesize all of the proteins of the alternative comple-
ment pathway, namely factors C3, D (adipsin), and B
(19). The proximal, nonlytic portion of the pathway is
operative in adipose tissue, and, in vitro, the proteo-
lytic cascade results in the production, among others,
of biologically active C3a, Ba, and Bb (19). In cultured
fat cell lines and other tissues, the activity of the
alternative complement pathway requires stimulation
by cytokines. However, the proximal pathway is fully
functional in adipose tissue fragments, even without
stimulation by cytokines, probably as a result of endog-
enous cytokine production. Further research is re-
quired to determine the primary functions and regula-
tion of the alternative complement pathway in adipose
tissue. The fact that partially acquired lipodystrophy is
associated with constitutive activation of the alterna-
tive complement pathway points to a potential patho-
physiological role of this pathway (19, 153).
ASP
A 14-kDa serum protein resulting from the cleavage
of the terminal arginine residue from C3a by plasma
carboxypeptidases was named the acylation-stimulat-
ing protein (ASP) (41). Because C3a is the end product
of the alternative complement pathway, of which factor
D, adipsin, is a main component, it was proposed that
it should be designated the “adipsin-ASP pathway”
(148).
Several roles for ASP in adipocyte metabolism have
been proposed (41). It may be involved in the uptake
and esterification of fatty acids to make triglycerides
and facilitate fatty acid storage in the postprandial
state. ASP increases after a fat-containing meal and
stimulates triglyceride synthesis via diacylglycerol
acyltransferase in adipocytes and fibroblasts. Although
ASP is expressed by both preadipocytes and fibro-
blasts, ASP formation is, predominantly, a feature of
mature and fully differentiated adipocytes (106). ASP
stimulates triglyceride production to a greater extent
than insulin, as well as having an additive effect with
that of insulin (185). ASP also stimulates translocation
of glucose transporters to the cell surface, probably by
activation of the diacylglycerol-protein kinase C path-
way (49). The fact that ASP is more potent in triglyc-
eride synthesis stimulation supports a role for ASP in
determining the rate at which fatty acids, derived from
circulating triglycerides hydrolyzed by LPL, are ester-
ified and stored in adipose tissue. Studies in ASP
functional knockout mice support the putative role in
triglyceride storage. Knockout mice have shown a de-
Fig. 1. Mouse visceral white adipose tissue immunostained for in-
ducible nitric oxide synthase (iNOS). The stain appears in the thin
cytoplasmic rim of the adipocytes. Note that the stain is more intense
in some adipocytes (*) at a multilocular stage of differentiation.
A: 3440 (bar 5 20 mm); B: 31,100 (bar 5 10 mm).
Fig. 2. Leptin immunolabeling of mouse adipocytes. The staining










layed triglyceride clearance compared with wild-type
animals, and this difference is further exaggerated in
female mice. The delay in triglyceride clearance may be
due to the effect on LPL of increased nonesterified fatty
acid concentrations. Differences between adipose tis-
sue depots have been detected, with greater degrees of
ASP binding in subcutaneous compared with omental
fat, in females compared with males, and in morbidly
obese compared with nonobese individuals (111).
In contrast to rodent models, serum adipsin concen-
trations tend to be increased in obese human subjects,
whereas adipsin secretion per adipocyte is normal
(149). However, when we consider that adipsin produc-
tion is not elevated in proportion to the increased fat
cell size, in contrast to many other adipocyte proteins,
the relatively lower ASP production could play a lim-
iting role in the triglyceride synthesis rate as fat cells
enlarge. Consistent with this reasoning, in vivo studies
have shown that esterification of triglyceride fatty ac-
ids released by LPL is less efficient in obese than in
lean subjects (39, 127). Further research will help to
clarify whether the major role of ASP lies in regulating
local triglyceride uptake by adipocytes, as well as
whether adipose tissue contributes to the pool of serum
ASP and thus to systemic triacylglycerol clearance.
Furthermore, the exact nature of the participation of
the adipsin-ASP pathway in fat cell size regulation,
together with the concrete mechanism of action of ASP,
still remains unknown.
Adipose Fatty Acid-Binding Protein
Fatty acid-binding proteins are abundant low-molec-
ular-weight cytoplasmic proteins that are thought to be
involved in the intracellular transport and metabolism
of fatty acids (129). Different members of this gene
family are expressed in a tissue-specific manner, with
several tissues expressing more than one fatty acid-
binding protein type. The adipose-specific fatty acid-
binding protein, also known as aP2, is expressed dur-
ing adipocyte differentiation and comprises up to 6% of
cytosolic protein in the mature fat cell (152). Adipose
fatty acid-binding protein has been shown to be in-
volved in intracellular trafficking and targeting of fatty
acids (183). This cytosolic adipose fatty acid-binding
protein is postulated to shuttle fatty acids within the
aqueous cytosol toward the membranes of the relevant
intracellular organelles that are involved in triglycer-
ide synthesis or fatty acid oxidation. This transfer is
believed to occur via a collisional mechanism depen-
dent on the interaction of organelle membrane phos-
pholipids with the basic residues of aP2, resulting in
partitioning of fatty acids to organelles for metabolic
utilization (183). Knockout of aP2 (aP22/2) results in
increased expression of keratinocyte fatty acid-binding
protein (63). Under normal circumstances, the keratin-
ocyte fatty acid-binding protein is principally ex-
pressed in skin and at low levels in adipose tissue.
aP22/2 mice show few phenotypic changes when fed a
standard low-fat diet, with the exception of slightly
lower plasma glucose and triglyceride concentrations
in the fasted state (63). However, in contrast to wild-
type controls, high-fat feeding did not lead to hyper-
insulinemia and insulin resistance in aP22/2 mice,
despite similarly elevated body weights. No major ab-
normalities in adipocyte triglyceride synthesis or lipol-
ysis were observed in aP22/2 mice with compensation
by keratinocyte fatty acid-binding protein (144). There-
fore, deficiency of aP2 was not associated with protec-
tion from mild insulin resistance resulting from short-
term high-fat feeding. Thus, with the possible
exception of de novo fatty acid synthesis, keratinocyte
fatty acid-binding proteins are capable of adequately
substituting for aP2. Consistent with these findings,
adipose tissue expression of TNF-a mRNA, a proposed
mediator of insulin resistance, was reported to be in-
creased in obese wild-type mice but not in aP22/2
Fig. 3. Dynamic view of the adipocyte, showing signals
emanating from white adipose tissue. PG, prostaglan-
din; ASP, acylation-stimulating protein; IGF-I, insulin-
like growth factor I; apoE, apolipoprotein E; TGF-b,
transforming growth factor-b; adipoQ, adipocyte com-
plement-related protein of 30 kDa, also called Acrp30;
PAI-1, plasminogen activator inhibitor-1; TNF-a, tu-
mor necrosis factor-a; sR, soluble receptors; IL-6, inter-










animals (63). These observations point to the fact that
fatty acid-binding proteins are involved in mediating
obesity-induced alterations in adipocyte gene expres-
sion. Furthermore, because it is reasonable to think
that fatty acid-binding proteins may modulate lipolytic
rate, and because increases in fatty acid flux are
thought to play a role in obesity-induced insulin resis-
tance, it was postulated that these would cause an
impairment in lipolysis (63).
Adipocyte Complement-Related Protein of 30 kDa
While a substraction cDNA library of mRNAs in-
duced during differentiation of 3T3-L1 adipocytes was
screened, an adipocyte complement-related protein of
30 kDa (Acrp30), another secretory protein belonging
to the collectin family and expressed by fat cells, was
found (67, 140). Acrp30, also called adipoQ, adiponec-
tin, and adipose most abundant gene transcript 1
(apM1), is a relatively abundant serum protein that
accounts for ;0.01% of the total plasmatic protein and
shows similarity to complement factor C1q. Its expres-
sion is markedly reduced in adipose tissue of obese
mice and humans (140). Its function is still unknown;
however, like adipsin, its secretion is modulated by
insulin, pointing to the possibility that its expression is
regulated by the nutritional state. Adiponectin has
been shown to suppress the attachment of monocytes
to endothelial cells, which is an early event in athero-
sclerotic vascular change, thus suggesting a protective
role against vascular damage. Furthermore, decreased
plasma adiponectin concentrations may be an indicator
of macroangiopathy in type 2 diabetic patients (66).
Agouti Protein
The agouti gene encodes a secreted protein that acts
in a paracrine manner to antagonize the melanocyte-
stimulating hormone receptor, thereby regulating
mouse coat color (102). Under normal circumstances,
the agouti protein is expressed only in skin of mice.
Dominant mutations in the agouti locus cause agouti to
be expressed in all tissues, producing a syndrome con-
sisting of yellow fur, obesity, hyperinsulinemia, and
insulin resistance (86). Ectopic expression of agouti in
transgenic mice reproduces this syndrome (86). In con-
trast to mice, the human agouti gene is normally ex-
pressed in adipose tissue and testis, suggesting a role
for this protein in regulating adipose tissue function.
The participation of the agouti protein in the develop-
ment of insulin resistance has been proposed to be
through increasing intracellular free calcium concen-
trations (191).
Angiotensinogen
Angiotensinogen is primarily synthesized by the
liver, although angiotensinogen mRNA is present in
several tissues, including adipose tissue (76). Angio-
tensinogen is the substrate of renin in the renin-angio-
tensin system and is converted into angiotensin I, the
precursor of angiotensin II. The physiological and
pathological role of angiotensinogen gene expression in
adipose tissue has not been completely elucidated. An-
giotensin II has been suggested to influence adipocyte
differentiation by interactions with angiotensin recep-
tors, inducing fat cells to produce prostacyclin (24).
Angiotensinogen expression is increased in obesity
and, in contrast to the hepatic expression, is regulated
by the nutritional status (41). During fasting, a de-
crease in mRNA above control has been observed,
which increases upon refeeding. Furthermore, these
changes in gene expression are paralleled by fluctua-
tions in angiotensinogen secretion from isolated adipo-
cytes. Angiotensinogen mRNA in both subcutaneous
and omental fat correlates with the waist-to-hip ratio,
with higher mRNA expression in the omental than in
the subcutaneous adipose depot (171). Angiotensino-
gen may play a role in local adipose tissue blood flow
and, hence, in rates of fatty acid reesterification (171).
Thus, by affecting both substrate availability and prea-
dipocyte differentiation, angiotensinogen is able to reg-
ulate adipose size in response to nutritional signals.
PAI-1
PAI-1 is a member of the family of serine protease
inhibitors or serpins. By inhibiting the tissue plasmin-
ogen activator, it is the main regulator of the endoge-
nous fibrinolytic system (182). Therefore, increased
concentrations of PAI-1 favor the development of
thromboembolic complications. Among the multiple
mechanisms that may explain the relationship be-
tween obesity and cardiovascular disease, disorders of
the fibrinolytic system seem to play a key role (78).
Elevated plasma concentrations of PAI-1 have been
found in obese subjects. A close correlation with an
abdominal pattern of adipose tissue distribution in
both men and women, as well as a positive association
with other components of the insulin resistance syn-
drome, have been reported (78, 146, 170). The mecha-
nisms responsible for the increase in PAI-1 are not yet
completely established. Expression and secretion of
PAI-1 in adipose tissue from humans and rodents have
been demonstrated. However, little is known about its
regulation at the adipocyte level. Insulin and TGF-b
appear to be the main inducers of PAI-1 synthesis in
adipose tissue (136). TNF-a, as well as IL-1b, also has
a stimulatory effect on PAI-1 protein secretion and
may contribute to the augmented PAI-1 concentrations
observed in obesity and insulin resistance (9). Insulin
has been reported to elevate PAI-1 production in cul-
tured hepatocytes, suggesting that increased hepatic
synthesis of PAI-1 might account for its elevation in
obese subjects (41). Recently, however, elevated PAI-1
concentrations associated with obesity have been
shown to result in part from insulin-mediated induc-
tion of PAI-1, specifically by adipocytes within the fat
itself (9). It has been shown that, in dieting obese
women, the decrease in PAI-1 during weight loss is
more closely related to changes in fat mass than to
changes in metabolic variables, suggesting a signifi-
cant role of adipose tissue in regulating plasma PAI-1










exists between PAI-1 antigen and circulating leptin
concentrations irrespective of body mass index, and
body fat mass seems to indicate that leptin per se may
potentially increase PAI-1 in obese subjects (25, 150).
TGF-b
TGF-b is a multifunctional cytokine produced by a
variety of cells that is capable of regulating the growth
and differentiation of numerous cell types (137, 154). It
has been implicated in a number of biological pro-
cesses, including cell adhesion and migration, extracel-
lular matrix production, tissue remodeling, and wound
repair.
TGF-b mRNA expression has been shown to be
higher in adipose tissue of ob/ob and db/db mice com-
pared with their lean littermates (137). Moreover, this
increase was due to elevated expression of TGF-b
mRNA by mature adipocytes and cells of the stromal/
vascular fraction. TNF-a contributes to the augmented
expression of TGF-b in adipose tissue of obese mice. In
this sense, chronically elevated TNF-a concentrations
in adipose tissue of obese individuals may act in an
autocrine/paracrine manner and contribute to in-
creased TGF-b expression in obesity. The elevated
gene expression of TGF-b in adipose tissue may have
broad implications in the pathophysiology of obesity
and its associated complications. TGF-b has been
shown to increase preadipocyte cell proliferation. Thus
the augmented expression of TGF-b in the obese adi-
pose tissue may increase adipocyte precursor cell pro-
liferation, thereby contributing to the elevated cellu-
larity of fat depots related to the obese phenotype. Both
obesity and type 2 diabetes are also associated with
characteristic long-term complications, including mi-
crovascular kidney disease. Interestingly, overexpres-
sion of TGF-b in glomeruli has been reported (41).
As mentioned before, TGF-b stimulates PAI-1 bio-
synthesis in a variety of cells, including adipocytes.
Insulin failed to raise TGF-b mRNA expression in lean
mice, even though significantly increasing the expres-
sion of PAI-1 mRNA in adipose tissue (137). Adminis-
tration of TGF-b to lean mice has been shown to cause
a 60-fold increase in plasmatic active PAI-1 and in-
creased PAI-1 mRNA in adipose tissue (137). The TGF-
b-mediated induction of PAI-1 in 3T3-L1 adipocytes
was considerably higher than the response of these
cells to TNF-a and insulin. Similarly, the greatest
PAI-1 response in adipose tissue in in vivo studies was
to TGF-b (36-fold), followed by TNF-a (9-fold), and
insulin (7-fold) (136, 137).
Growth Hormone
Growth hormone (GH) is an important regulator of
body mass throughout life (4, 14). It has been observed
that GH deficiency in both children and adults is char-
acterized by abnormal body composition, with in-
creased fat mass and decreased lean muscle mass.
GH-deficient subjects exhibit increased visceral and
subcutaneous adipose tissue depots, which are partly
normalized by GH therapy (2, 4). Whereas subcutane-
ous adipose tissue decreased by an average of 13%,
visceral fat depots were reduced by 30%. In contrast, in
patients with acromegaly, a reduced fat mass was
observed to return to normal after treatment of the
hormone excess by octreotide or pituitary surgery. Adi-
pocytes have specific GH receptors, with the hormone
exerting a variety of direct metabolic effects, such as
inhibition of glucose uptake and stimulation of lipoly-
sis, which may cause a net loss of stored lipids (2).
Sex Steroids
Two enzymes of relevance to sex steroid metabolism
are present in adipose tissue, 17b-hydroxysteroid oxi-
doreductase and cytochrome-P-450-dependent aro-
matase (111). Androstenedione, synthesized in the ad-
renal cortex, is converted by 17b-hydroxysteroid
oxidoreductase to testosterone. This same enzyme con-
verts estrogen and estrone to estradiol. Aromatization
of androgens to estrogens also takes place in white
adipose tissue. The presence of estrogens in the plasma
of postmenopausal women led to the discovery that
adipose tissue was an active extraglandular producer
of certain steroid hormones (87, 111). Circulating C19
precursors of adrenal origin are converted to estrone
and estradiol via adipose tissue P-450 aromatase (111).
A net release of testosterone, estradiol, and estrone
from abdominal subcutaneous adipose tissue in
women, but not in men, has been shown in arterio-
venous studies (132). A clear sexual dimorphism in
relation to the influence of sex steroids on adipose
tissue function has been observed.
ADIPOCYTES AS A SOURCE OF CYTOKINES
Cytokines are defined as soluble proteins synthe-
sized by immune or nonimmune cells, which mediate
intercellular communication by transmitting informa-
tion to target cells through receptor-ligand interac-
tions. This class of mediators is represented by cyto-
lytic, chemotactic, and immunoenhancing growth and
differentiation factors. Many cytokines have physiolog-
ical activities far beyond those originally discovered. A
prominent role for cytokines in the regulation of energy
balance has evolved from recent investigations. Proin-
flammatory cytokines with potent actions in host de-
fense, like TNF-a and IL-6, have also important effects
on both lipid and glucose metabolism (53, 111).
IL-6
The term interleukin originally described a leuko-
cyte-derived protein with activity for other leukocytes.
It is now understood that both immune and nonim-
mune cells synthesize interleukins and other cyto-
kines, which have diverse biological activities.
Interleukin-6 expression in adipose tissue. Interest-
ingly, production of IL-6, as well as systemic concen-
trations, has been shown to be positively correlated
with body mass index (175). As much as a third of total
circulating concentrations of IL-6 has been estimated
to originate from adipose tissue (110, 184). In this










regulator of adipocyte function. Omental fat produces
threefold more IL-6 than subcutaneous adipose tissue,
and adipocytes isolated from the omental depot also
secrete more IL-6 than fat cells from the subcutaneous
depot (40). Although it has now been clearly estab-
lished that adipocytes themselves secrete IL-6 on a per
lipid weight or per fat cell basis, this cell type accounts
for only 10% of the total adipose tissue production, as
evidenced by determination of IL-6 released by intact
adipose tissue fragments and isolated adipocytes pre-
pared from omental and subcutaneous fat depots (40).
Thus other cells within the adipose tissue also contrib-
ute to the high release of IL-6. This is not surprising,
because IL-6 is a multifunctional cytokine produced by
many different cell types, including immune cells, fi-
broblasts, stromal-vascular cells, endothelial cells,
myocytes, and a variety of endocrine cells (172). The
amount of IL-6 produced by adipose tissue is similar to
or greater than that reported for a variety of other
tissues and cells, with the concentrations of IL-6 accu-
mulating in adipose tissue or cell incubations (up to 75
ng/ml) being well within the range to elicit biological
effects (51). Regardless of the cellular source of IL-6, it
is interesting to note that adipose tissue may be an
important source for the increased serum concentra-
tions of IL-6 observed in obesity, with depot-specific
differences in terms of both quantitative contribution
to the serum pool and qualitative participation in lipid
metabolism. Because the venous drainage from omen-
tal adipose tissue flows directly into the liver, the
metabolic impact of IL-6 release from this fat depot
may be of particular importance. In this sense, it has
been shown that IL-6 increases hepatic triglyceride
secretion (116) and may, therefore, contribute to the
hypertriglyceridemia associated with visceral obesity.
IL-6 is secreted by adipose tissue under basal condi-
tions. It has been shown that TNF-a produces a 60-fold
increase in IL-6 production in differentiated 3T3-L1
adipocytes (53). Thus it is feasible that adipose tissue
TNF-a, whose expression is elevated in obesity, in-
duces adipocyte and nonadipocyte IL-6 expression.
Other important modulators of IL-6 expression in
different fat depots are glucocorticoids and cat-
echolamines (40, 119). Dexamethasone markedly sup-
presses IL-6 production, whereas insulin has no effect,
suggesting that cortisol may act physiologically in the
modulation of IL-6 production. In primary cultures of
murine adipocytes, norepinephrine, isoprenaline, and
a b3-selective agonist have been shown to stimulate
IL-6 gene expression and protein secretion, whereas
activation of a-adrenergic receptors had no effect (111).
IL-6 receptors. Class I cytokine receptors are known
to act through Janus kinases (JAK) and signal trans-
ducers and activators of transcription (STAT). JAK
proteins are associated with membrane-proximal se-
quences of the receptor intracellular domain, which is
phosphorylated upon ligand binding. The phosphory-
lated intracellular domain then provides a binding site
for a STAT protein, which is activated, translocates to
the nucleus, and stimulates transcription. The biolog-
ical activities of IL-6 are initiated by binding to a
high-affinity receptor complex consisting of two mem-
brane glycoproteins (160). The IL-6 receptor (IL-6R),
the 80-kDa ligand-binding component, binds IL-6 with
low affinity, but the 130-kDa signal-transducing com-
ponent, gp130, although not binding free IL-6, is re-
quired for high-affinity binding of gp80-bound IL-6. It
has been reported that IL-6-type cytokines use tyrosine
kinases of the JAK family for signal transduction (71).
Dimerization of the intracellular domains of two gp130
molecules brings the receptor-associated JAKs (JAK1,
JAK2, and Tyk2) into close proximity, leading to acti-
vation via inter- or intramolecular phosphorylation
and activation. Specific STAT proteins are recruited to
the stimulated receptor complexes and are activated by
direct phosphorylation by receptor-asscociated JAKs.
The leukemia inhibitory factor (LIF), a member of the
IL-6 family of cytokines, has been shown to activate
the JAK/STAT pathway (71). After the activation of the
signal transduction receptor gp130, LIF induces a
rapid tyrosine phosphorylation of JAK1, JAK2, Tyk2,
STAT1, and STAT3.
A soluble form of IL-6R (IL-6Rs), apparently arising
from proteolytic cleavage of the membrane-bound re-
ceptor and with a molecular mass of ;50 kDa, has been
found (157). The recombinant IL-6Rs has been shown
to increase the activity of IL-6 as a result of the binding
of the IL-6/IL-6Rs complex to the membrane-bound
gp130 (160). Elevated concentrations of IL-6 have been
suggested to be associated with increased production of
IL-6Rs (133). Recently, evidence for a soluble form of
the gp130 receptor, which may exert antagonist prop-
erties, has also been reported (186). In humans, sub-
cutaneous adipose tissue has been shown to release
IL-6 but not soluble receptors (109, 110). Therefore, a
regulatory role for adipocytes in the bioavailability of
cytokines has been put forward (111). However, nei-
ther the functional significance nor the regulation of
soluble receptors is clearly understood.
Biological effects of IL-6. IL-6 decreases adipose tis-
sue LPL activity and has been implicated in the fat
depletion taking place during cancer cachexia and
other wasting disorders (51, 158). Like TNF-a, IL-6 has
potent effects on adipose tissue, as evidenced by the
fact that neutralization of this cytokine decreases the
loss of adipose tissue during cachexia (158). It seems
unlikely that this effect is mediated solely by the doc-
umented ability of IL-6 to downregulate LPL activity,
implying that IL-6 exerts other actions on adipocyte
metabolism. IL-6 is considered to be an inflammatory
mediator as well as a stress-induced cytokine (189). It
has pleiotropic effects on a variety of tissues, including
downregulation of adipocyte LPL, stimulation of acute-
phase protein synthesis, increase in the activity of the
hypothalamic-pituitary axis (HPA), and thermogene-
sis, consistent with the candidate role of corticotropin-
releasing hormone (CRH) as a common mediator of











TNF-a is a cytokine, first identified as a macrophage
product implicated in the metabolic disturbances of
chronic inflammation and malignancy. The biological
actions of TNF-a include induction of insulin resis-
tance, anorexia, and weight loss. Since the discovery
that TNF-a is involved in the loss of body fat in the
course of wasting disorders, a large number of studies
investigated the physiological role of this cytokine in
adipose tissue (65, 81, 165).
TNF-a expression in adipose tissue. Hotamisligil et
al. (65) were the first to describe adipose expression of
TNF-a mRNA in different rodent models of obesity.
Clinical studies have also revealed expression of TNF
mRNA in human adipose tissue (62, 68, 81). Subcuta-
neous fat depots exhibit a 1.67-fold higher TNF-a
mRNA expression than omental fat depots (68). The
amount of TNF-a mRNA is positively correlated with
body adiposity and decreases in obese subjects after
weight loss (112). TNF-a mRNA expression is also
closely correlated with hyperinsulinemia, showing pos-
itive associations with fasting insulin and triglyceride
concentrations (62).
Expression of TNF-a takes place already in adipo-
cyte precursor cells, although the amount of specific
mRNA increases only moderately in a differentiation-
dependent manner (69, 70). Interestingly, compounds
that are used for the induction of adipose differentia-
tion, such as the nonselective phosphodiesterase inhib-
itor IBMX and the thiazolidinediones, are inhibitors of
TNF-a expression. In this sense, it is tempting to
speculate that the adipogenic effect of these com-
pounds may be at least partially mediated by a sup-
pression of endogenous TNF-a production. Triglycer-
ides and free fatty acids play an important role as
physiological inducers of TNF-a expression. Feeding
high-fat diets (45% of the energy content) is followed by
a significant increase of TNF-a mRNA in fat pads of
rats (113). Moreover, mice lacking the adipocyte fatty
acid-binding protein aP2 do not express TNF-a in
white adipose tissue (63), indicating that fatty acids
are critically involved in the regulation of TNF-a ex-
pression in adipose tissue.
Expression pattern of TNF-a receptors. In addition to
measuring TNF-a mRNA, it is also important to study
the expression pattern of TNF receptors (TNFR) in
adipose tissue. TNF-a interacts with two cell-surface
receptors, p55 (p60 in humans) and p75 (p80 in hu-
mans) (52). Regulation of the expression of these two
receptors seems to underlie separate mechanisms, be-
cause they present different cellular and tissue distri-
bution patterns. The p60 TNFR appears to be primar-
ily involved in insulin receptor signaling and glucose
transport (121), and the p80 TNFR has been shown to
be involved in the pathogenesis of TNF-induced insulin
resistance (61, 96). The lack of p75 TNFR in diet-
induced obese mice leads to body weight loss with
improved insulin concentrations and sensitivity (142).
Obese mice deficient in p55 TNFR showed slightly
elevated insulin concentrations after 3 mo of a high-fat
diet, whereas mice lacking both receptors were signif-
icantly hyperinsulinemic during the 4 mo of high-fat
feeding (142). The researchers concluded that TNFR
may be required for glucose homeostasis but do not
exert a critical role in the development of insulin resis-
tance. Conversely, the lack of p55 TNFR in ob/ob mice
has been shown to cause an improvement of insulin
sensitivity, whereas a lack of the p75 TNFR alone did
not alter insulin action but potentiated the effect of p55
TNFR deficiency in animals deficient in both receptors
(168). Subsequent studies performed in preadipocyte
cell lines from these knockout mice confirmed that
TNF-induced insulin resistance, as well as alterations
in the adipogenic program, can be attributed predom-
inantly to the actions of the p55 TNFR (69).
The question arising is whether similar observations
can be made in humans. Compared with lean controls,
obese individuals with or without type 2 diabetes mel-
litus show significantly higher mRNA levels of both
TNFR (68). The relative expression of p60 TNFR was
strongly correlated with body mass index, whereas p80
TNFR mRNA varied widely in each group of subjects
but was closely related to the amount of plasma tri-
glycerides and, to some extent, was positively associ-
ated with the expression of its ligand. Apparently,
selective activation of the p60 TNFR inhibited differ-
entiation in human preadipocytes, whereas activation
of the p80 TNFR resulted in increased differentiation
(69). Inhibition of insulin-stimulated glucose transport
in human cultured adipocytes was independently me-
diated by both receptors. However, published data are
not always in agreement; some investigators have
found a twofold increase in p80 TNFR mRNA levels in
the obese state but no difference in p60 TNFR mRNA
(61). These findings point to the possibility that both
TNFR are involved in the development of TNF-induced
insulin resistance through different mechanisms, al-
though their exact interaction and relative contribu-
tion still remain to be completely disentangled.
The determination of circulating TNF-a and TNFR
concentrations provides additional information regard-
ing the role of the TNF system in human obesity. In
contrast to the findings made in rodent models of
obesity, where a marked increase in circulating TNF-a
concentrations has been found (65), in obese diabetic
and nondiabetic patients, TNF-a concentrations are
not substantially elevated (55, 123). The expression of
TNF-a in human white adipose tissue is relatively low.
Thus it remains doubtful whether adipose tissue is a
major source of circulating TNF-a (68). This reasoning
is also supported by an in vivo study measuring arte-
riovenous differences across a subcutaneous adipose
tissue bed, which evidenced a nonsignificant contribu-
tion of white adipose tissue to the serum concentra-
tions of TNF-a (110).
Disagreements regarding the serum concentrations
of the proteolytically cleaved soluble TNFR in obese
and insulin-resistant patients have also been obtained.










ing concentrations of both soluble receptor subtypes in
obese compared with lean individuals (55), whereas
another group has found sixfold concentrations of the
soluble p80 TNFR in obese compared with lean sub-
jects, but no differences in the circulating concentra-
tions of the soluble p60 TNFR (61). The physiological
relevance of these findings remains unknown. Both
soluble receptor subtypes bind to TNF-a in vitro and
inhibit its biological activity by competing with cell-
surface receptors for TNF-a. Therefore, the release of
soluble receptors may represent a mechanism of bind-
ing and inhibiting the TNF-a not immediately bound to
surface receptors, thereby protecting other target cells
and circumscribing its effect (173). It is conceivable
that soluble receptors serve to neutralize circulating
TNF-a. The release of soluble receptors may imply a
desensitizing mechanism of cells to the effects of
TNF-a. Conversely, low TNF-a concentrations, binding
to soluble receptors, have been reported to stabilize
TNF-a and increase its activity (69). Thus augmented
concentrations of the soluble receptors may reflect ei-
ther a state of receptor inactivation or an upregulated
TNF system in obesity.
Biological effects of TNF-a. TNF-a has pronounced
catabolic effects in adipose tissue (69). It suppresses
LPL at the mRNA and protein levels, as reported in
many in vivo and in vitro studies. TNF-a inhibits the
expression of the two master regulators of adipose
differentiation, the transcription factor CCAAT/en-
hancer binding protein-a (CEBPa) and the nuclear
receptor peroxisome proliferator-activated receptor-g2
(PPARg2) (156, 184). This suppression may result in
the subsequent downregulation of many adipocyte-spe-
cific proteins, such as LPL, aP2, fatty acid synthetase,
acetyl-CoA carboxylase, glycerol-3-phosphate dehydro-
genase (GPDH), and GLUT-4 among others. Further-
more, mature adipocytes are stimulated to mobilize
lipids upon TNF-a exposure, possibly via hormone-
sensitive lipase activation (56). Among the multiple
properties of TNF-a, the antiadipogenic effect is espe-
cially relevant, because adipose conversion of fat cell
precursors is potently inhibited by TNF-a (122). More-
over, chronic treatment of mature fat cells with TNF-a
has been shown to lead to a reversion of the adipocyte
phenotype back to a fibroblast-like morphology (122).
Although it was formerly assumed that TNF-a selec-
tively mediates apoptosis in tumor cells, it has been
suggested that this could also be of relevance for hu-
man preadipocytes and adipocytes (128). Programmed
cell death could represent another mechanism by
which TNF-a can modulate adipose tissue cellularity.
Thus TNF-a could decrease adipose tissue mass by
reducing not only fat cell volume but also adipocyte
number.
Adipose tissue expansion may occur by adipocyte
hypertrophy, hyperplasia, or both (14, 60). Fat cells
reaching a critical size trigger the events that result in
proliferation of adipocytes. An increase in fat cell size
before the onset of adipocyte hyperplasia has been
observed in diet-induced obese rats (47). Adipose tissue
levels of TNF-a and IGF-I have been shown to be
higher in both human and rodent obesity (45, 87, 105),
but these paracrine factors have seemingly opposing
effects on adipose tissue development. IGF-I induces
both mitogenic and differentiation responses in pre-
adipocyte cultures (178), whereas TNF-a inhibits the
expression of adipogenic enzymes (184). It can be hy-
pothesized that TNF-a may exert a permissive role in
adipose tissue expansion, whereby its production in-
creases when existing fat cells reach a critical size.
Because TNF-a is a very potent inhibitor of differenti-
ation, it may act to drive cells into a mitogenic program
directly or by other mechanisms such as increasing
growth factor responsiveness. Recently, it has been
shown that IGF-I, produced in response to enlarging
fat cells, acts synergistically with TNF-a to further
enhance proliferation (89). The net result from this
interaction would be an increase of the stromal-vascu-
lar or uncommitted cell pool whereby these cells might
then be recruited to become adipocytes or might alter-
natively serve as infrastructure to support adipose
tissue growth. Furthermore, it has been suggested that
loss of the ability of IGF-I to activate Shc signaling to
mitogen-activated protein kinase (MAPK) may be an
early component of adipogenesis (13).
Leptin
A major development in energy balance regulation
has come with the discovery in 1994 of leptin, the
protein product of the ob gene (196). The initial concept
was that leptin informs the brain about the abundance
of body fat, thereby allowing feeding behavior, metab-
olism, and endocrine physiology to be coupled to the
nutritional state of the organism (1, 44). Leptin con-
sists of four antiparallel a-helices, connected by two
long crossover links and one short loop, arranged in a
left-hand twisted helical bundle. The interhelical an-
gles and features of the long crossover loops are similar
to those found in the long-chain helical cytokine crys-
tal structures, which include granulocyte colony-stim-
ulating factor (GSCF), LIF, ciliary neurotropic factor
(CNTF), and human GH (101, 193).
Leptin expression in adipose tissue. Leptin biosyn-
thesis and release are governed by paracrine, endo-
crine, and neuroendocrine signals that impinge on the
adipocyte (1, 44, 111, 166). Because leptin is secreted
by fat cells in proportion to body fat stores, it has the
potential to play a key regulatory role in fuel homeosta-
sis (166). As would be predicted of a factor involved in
energy balance, expression of the ob gene is subject to
nutritional regulation. Fasting induces a fall in the
level of ob mRNA, which is rapidly reversed on refeed-
ing, and circulating leptin levels change in parallel
with tissue mRNA (44, 166). Glucosamine infusion
increases leptin expression in adipose tissue and in-
duces de novo leptin synthesis in rat skeletal muscle
(179). Glucose infusion and lipid infusion have similar
effects on leptin expression in adipose tissue and mus-
cle, raising the possibility that leptin acts as a sensor of










Evidence for a direct autocrine/paracrine effect of
leptin on the lipolytic activity of isolated adipocytes has
recently been reported (43). In addition, leptin has
been shown to repress acetyl-CoA carboxylase gene
expression, fatty acid synthesis, and lipid synthesis;
these are biochemical reactions that contribute to lipid
accumulation without the participation of centrally
mediated pathways (145, 180, 181). Thus leptin is
involved in the direct regulation of adipose tissue me-
tabolism by both inhibiting lipogenesis and stimulat-
ing lipolysis (44). Insulin stimulates ob gene expres-
sion, as do estrogens and glucocorticoids, with the
effects of the latter being maintained during chronic
treatment. Although plasma leptin, thyroid-stimulat-
ing hormone (TSH), and adiposity correlate in euthy-
roid patients, there are conflicting reports on the effect
of hypo- and hyperthyroidism on ob gene expression
(1). Androgens and GH decrease ob gene expression (1,
6, 44). Similarly, cold exposure induces a sympatheti-
cally mediated suppression of the ob gene, leading to a
rapid decrease in both ob mRNA and serum leptin
concentrations (166).
Plasma leptin concentrations and adipocyte ob mRNA
expression are strongly correlated with estimates of
obesity, and total fat mass, percent body fat, and body
mass index are the best predictors (1). Leptin mRNA
shows higher expression in subcutaneous than in
omental adipocytes (112). In addition, a striking sexual
dimorphism is evident in both ob mRNA expression
and circulating leptin concentrations, with almost two-
fold higher leptin concentrations in women (44). Adi-
pocyte size is an important determinant of leptin syn-
thesis, because larger fat cells contain more leptin than
smaller adipocytes from the same individual (1, 23).
However, it is not known whether increased triglycer-
ide contents, lipid metabolites, or mechanical factors
associated with augmented adipocyte size influence
leptin expression. It has been shown that a propor-
tional increase in adipocyte size is insufficient to ex-
plain the sex- and site-specific differences observed
(112). Omental fat depots represent a more rapidly
mobilizable source of energy in the form of free fatty
acids, particularly in response to stress hormones.
Thus the observation of increased leptin mRNA in
subcutaneous compared with omental adipocytes may
imply that omental adipose tissue is a less important
contributor to the long-term feedback loop controlling
appetite and metabolic rate than subcutaneous adipose
tissue. Although this property of omental fat may be
advantageous in allowing a more efficient use of avail-
able calories in times of alternating food scarcity and
plenty, in modern sedentary humans with an ensured
food supply, reduced leptin mRNA expression, and
hence leptin production from omental adipocytes, may
contribute to the high prevalence of central obesity
with its associated pathological consequences. Some
researchers attribute the observed gender differences
to the stimulating role of estrogens and the suppres-
sive effect of circulating androgens, but other investi-
gators have not been able to ascribe the sexual dimor-
phism to sex hormones (44, 103). Further studies will
be required to address the molecular basis for and
physiological consequences of depot- and sex-specific
variation in ob mRNA expression in humans.
Cell-autonomous factors such as intracellular me-
tabolites, signaling molecules, or transcription factors
act as other major links between adipocyte size and
leptin gene expression (151). Like many other adipo-
cyte genes, the ob gene promoter is positively regulated
through a functional binding site for CEBPa (6). In
contrast, thiazoladinedione agonists for PPARg tran-
scription factors suppress leptin expression (26). This
may partly involve a functional antagonism between
CEBPa and PPARg on the leptin promoter, and this
mechanism may explain the downregulation of leptin
expression by thiazoladinediones (1, 6).
Furthermore, leptin production is influenced by im-
mune activation. In this context, a positive and inde-
pendent association between TNF-a and circulating
leptin concentrations has been reported (104).
Leptin receptors. Consistent with leptin’s pleiotropic
effects, leptin receptors (OB-R) exhibit an almost uni-
versal distribution. The OB-R belong to the class I
cytokine receptor family, which includes the receptors
of IL-6, LIF, GSCF, and gp130 (1, 161). OB-R are
produced in several alternatively spliced forms, desig-
nated OB-Ra, OB-Rb, OB-Rc, OB-Rd, and OB-Re. The
receptors share an identical extracellular ligand-bind-
ing domain of 840 amino acids at the amino terminus,
as well as a transmembrane domain of 34 amino acids,
but they differ at the carboxy terminus. A variable
intracellular domain, characteristic for each of the five
receptor isoforms, has been identified. Only the full-
length isoform, the OB-Rb, is believed to be involved in
leptin signaling and is considered to be the functional
receptor. Recent reports have shown that activation of
OB-Rb, and to a lesser extent OB-Ra, mediates ligand-
induced activation of both JAK and STAT proteins
(1, 8). The extracellular and cytoplasmic regions of
OB-R and gp130 possess conserved motifs and are
closely related to each other. OB-R and gp130 appear
to mediate overlapping but distinct cytoplasmic sig-
nals (114). Furthermore, recent reports have shown
that OB-R stimulate transcription via IL-6 and hema-
topoietin receptor-responsive elements (8). Thus OB-R
share, at least in part, some of the signaling pathways
characteristic of the class I cytokine receptor family.
The lack of the full-length OB-R has been shown to be
responsible for the db/db mouse obesity phenotype and
the fatty mutation (8, 161).
The OB-Re, which lacks the intracellular and trans-
membrane domains, circulates as a soluble receptor
(93). Secreted extracellular domains of cytokine recep-
tors are known to function as specific binding proteins
(58). In mice, it has been observed that the putative
soluble isoform, OB-Re, is produced at a level that is
sufficiently high to act as a buffering system for free
circulating leptin (97).
Biological effects of leptin. Leptin has diverse effects
in addition to appetite and body weight regulation.
Many cytokines, originally isolated on the basis of










shown to be capable of stimulating a variety of biolog-
ical responses in a wide spectrum of cell types. Thus
leptin shares with other cytokines an extreme func-
tional pleiotropy and has been shown to be involved in
quite diverse physiological functions, such as reproduc-
tion (17), hematopoiesis (20), angiogenesis (147), im-
mune responsiveness (98), blood pressure control (42),
and bone formation (30).
It has been shown that leptin is necessary for mat-
uration of the reproductive axis, as evidenced by its
ability to restore puberty and fertility in ob/ob mice,
accelerate puberty in wild-type mice, and facilitate
reproductive behavior in rodents (1). Therefore, leptin
signals the adequacy of energy stores for reproduction
by interacting with different target organs in the hy-
pothalamic-pituitary-gonadal axis (44).
The functional OB-R has been shown to be capable of
signaling for cell survival, proliferation, and differen-
tiation into macrophages (20, 46). In addition, leptin
appears to be able to enhance the production of cyto-
kines in macrophages and to increase the attachment
and subsequent receptor-mediated process of phagocy-
tosis (46). This activity may be mediated by an upregu-
lation of macrophage receptors or by increased phago-
cytic activity. In this sense, a role for leukocyte
adhesion receptors in maintenance of normal body
weight and adiposity has recently been described (28).
In addition, leptin has a direct proliferative effect on T
cells, showing an adaptive response of this hormone to
enhance the immune competence of the organism
against the immunosuppression associated with star-
vation (98).
Leptin has to be included in the list of angiogenic
factors secreted by adipose tissue, because it has been
shown to cause cultured endothelial cells to aggregate,
form tubes, and display a reticular array reminiscent
of tissue vasculature (147). It has also been observed
that leptin accelerates wound healing, a process de-
pending on blood vessel growth.
Regarding blood pressure homeostasis, leptin ap-
pears to have a balanced effect, with a pressor response
attributable to sympathetic activation and a depressor
response attributable to NO release (42). Therefore,
leptin is involved in the control of vascular tone by
simultaneously producing a neurogenic pressor action
and an opposing NO-mediated depressor effect. In this
sense, leptin may be one of the factors underlying the
association of obesity with increased incidence of hy-
pertension and cardiovascular mortality.
A recent study identified leptin as a potent inhibitor
of bone formation, acting through the central nervous
system (30). Despite suffering from hypogonadism and
hypercortisolism, known inducers of increased osteo-
clast number and bone resorption activity, leptin-defi-
cient and OB-R-deficient mice exhibit a high bone mass
phenotype. Interestingly, this phenotype is not second-
ary to obesity but is directly related to the lack of leptin
signaling. Intracerebroventricular infusion of leptin to
ob/ob and wild-type mice was followed by a significant
bone mass reduction (30).
CROSS TALK AMONG ADIPOCYTE-DERIVED
CYTOKINES
TNF-a, IL-6, and leptin share both structural and
functional similarities with other cytokines, including
receptor homology, signaling via the JAK/STAT sys-
tem, growth factor properties, and circulation in
plasma, either in the free form or bound to specific
serum proteins (7, 8, 44, 101, 161, 193). All three
cytokines are expressed and released by adipocytes,
exerting a key role in fat mass control. TNF-a induces
the release of both IL-6 and leptin from adipose tissue
(54, 138). Knockout mice for the TNF-a gene showed a
hypoleptinemia compared with wild-type mice (85).
Apparently, TNF-a induces leptin production through
the p55 TNF receptor (36). All three cytokines, TNF-a,
IL-6, and leptin, are closely interrelated as well as
influencing and being regulated by other hormones and
the sympathetic nervous system (Fig. 4) (111, 124,
194).
Proinflammatory cytokines have been shown to play
a major role in the initiation of the sepsis syndrome,
with the amount and speed of their release correlating
with the occurrence of septic shock and, eventually,
with mortality (16). However, TNF-a and IL-1 are
seldom found in the circulation of septic patients. It
has been proposed that enhanced production of endog-
enous inhibitors of these cytokines, such as soluble
TNFR and IL-1 receptor antagonist, as well as in-
creased secretion of the anti-inflammatory cytokine
IL-10, may be important host defense mechanisms to
attenuate concurrent proinflammatory cytokine activ-
ity during sepsis. Leptin synthesis is stimulated by
infection, endotoxin, and cytokines such as TNF-a,
LIF, and IL-1 (54, 74, 138). The rise in leptin concen-
trations as a result of cytokine increase may contribute
to the anorexia and weight loss accompanying these
Fig. 4. Postulated cross talk between the main adipocyte-derived
cytokines and interactions with sympathetic activity and insulin.
Solid lines indicate stimulation; dashed lines indicate inhibition.










inflammatory conditions. An independent association
for leptin with IL-1 receptor antagonist and IL-10 in
sepsis and septic shock has been described (5). In
addition, leptin and IL-6 have been shown to be inde-
pendent predictors of death in both study groups. Be-
cause patients with sepsis and septic shock have
higher plasma concentrations (2.3- and 4.2-fold, re-
spectively) than those expected on the basis of their fat
mass, it has been postulated that, in this case, circu-
lating leptin does not signal the magnitude of energy
stores to the hypothalamus but works rather as a
stress-related peptide. Survivors of severe sepsis and
septic shock exhibited leptin concentrations 1.3- and
1.6-fold greater than nonsurvivors in each group (5).
Thus the leptin response may be related to the extent
of activation of the immune system and may serve as a
marker of the severity and outcome of septic patients
(5), because leptin has been shown to stimulate prolif-
eration of lymphohematopoetic cells and phagocytic
activity of macrophages (46).
CYTOKINES IN ENERGY REGULATION
Although adipose tissue consumes little oxygen rel-
ative to other organs, it is an exceptionally efficient
participant in the regulation of fuel selection in whole
body physiology (38). Adipose tissue has the ability to
regulate its metabolism, cell size, and cell number
through the production of autocrine, paracrine, and
endocrine signals. By participating in food intake reg-
ulation, the adipocyte literally controls the substrate
flow available for storage of triglycerides.
Obesity results from both quantitative and qualita-
tive changes at the adipose tissue level. An excess of
adipose tissue frequently includes both hyperplasic
and hypertrophic development (14, 22). This circum-
stance tends to exacerbate the overproduction of cyto-
kines and other mediators, with the potential of exert-
ing their effects both locally and systemically, and thus
promoting the pathophysiological complications asso-
ciated with increased fat mass (Fig. 5). As mentioned
above, the efficiency of fat deposition is affected by local
secretion of adipocyte-derived factors, which influence
insulin signaling, decrease lipogenic gene expression,
increase lipolysis, control blood flow, and regulate in-
tracellular triglyceride synthesis. The mechanisms
that lead to obesity are complex and involve multiple
cytokines, hormones, and growth factors. The fact that
TNF-a, leptin, IL-6, insulin, PAI-1, TGF-b, and the like
are elevated in obesity and induce other adipocyte-
derived products in both plasma and adipose tissue
reveals the participation of a highly intricate network
of signals in the regulation of obesity. Undoubtedly,
there are many other mechanisms and factors that
regulate the level of energy stores by modulating the
deposition and mobilization of adipose triglyceride
pools and that need to be uncovered.
EFFECTS OF CYTOKINES ON INSULIN SIGNALING
There is growing experimental evidence from animal
studies that TNF-a plays a key role in the pathogenesis
of insulin resistance associated with obesity (69). Ho-
tamisligil et al. (65) were the first to report a close
relationship between increased adipose TNF-a expres-
sion and features of insulin resistance in rodent models
of obesity and type 2 diabetes mellitus (65). In obese
fa/fa rats, insulin resistance could be reversed by infu-
sion of a TNF-a-neutralizing IgG fusion protein con-
taining soluble TNFR domains. Subsequent investiga-
tions showed that TNF-a interferes with the tyrosine
phosphorylation of the insulin receptor in Fao hepato-
cytes and 3T3 cells (35). Further experiments demon-
strated that TNF-a induces phosphorylation of insulin
Fig. 5. Overproduction of adipocyte-derived factors











receptor substrate-1 (IRS-1) at serine residues and
that serine-phosphorylated IRS-1 operates as an inhib-
itor of insulin receptor activity (64, 80). By use of a
fibroblast cell line overexpressing the human insulin
receptor, a role for phosphotyrosine phosphatases in
the TNF-mediated inhibition of insulin signaling has
been postulated (90). Furthermore, in response to
acute insulin stimulation after cellular TNF-a expo-
sure, a normal tyrosine phosphorylation of the insulin
receptor and IRS-1, together with a reduced expression
of proteins involved in insulin action, such as IRS-1
and GLUT-4, has been reported, representing a plau-
sible explanation for the observed insulin resistance of
glucose transport (155). The potential role of IRS-2 in
TNF-induced insulin resistance has yielded conflicting
results. Although in hepatoma cells and brown adipo-
cytes IRS-2 has been shown to be involved in the
induction of insulin resistance through TNF-a (120), in
cultured white fat cells, IRS-2 did not mediate the
inhibition of insulin signaling by TNF-a (121).
So far, most studies on the mechanisms of insulin
resistance related to TNF-a have been carried out in
animal models. However, whether this holds true for
humans has not been completely elucidated. A rapid
inhibition of insulin signaling at the phosphatidylino-
sitol (PI) 3-kinase level by TNF-a treatment and a
concomitant inhibition of insulin-stimulated glucose
transport in isolated human adipocytes have been re-
ported (69, 96). The effect of TNF-a was correlated with
an inhibition of tyrosine phosphorylation of IRS-1 with
unaltered autophosphorylation of the insulin receptor
b-subunit (Fig. 6). Long-term exposure to TNF-a in
vitro of differentiated human adipocytes resulted in a
dramatic reduction of GLUT-4, whereas GLUT-1 ex-
pression was upregulated (56). On the contrary, intra-
venous administration of a recombinant-engineered
human TNF-neutralizing antibody to patients with
type 2 diabetes mellitus did not alter fasting glucose
and insulin concentrations. Furthermore, glucose
clearance during intravenous insulin sensitivity tests
remained unaffected by the TNF-neutralizing antibody
treatment, arguing against a prominent role of circu-
lating TNF in the development of insulin resistance in
humans (118).
Although the mechanisms of TNF-mediated insulin
resistance are only incompletely understood, TNF-a is
a potentially attractive target for pharmacological in-
tervention aimed at protecting against obesity-induced
insulin resistance (124, 169). Numerous strategies are
currently in progress in controlled clinical trials to
suppress the production or activity of TNF-a in a va-
riety of diseases (33). It will be interesting to establish
whether suppression of TNF-a improves insulin sensi-
tivity in humans and how it influences adipose tissue
metabolism.
Ligand binding to the OB-Rb results in the activa-
tion of JAK2 by transphosphorylation and the subse-
quent tyrosine phosphorylation of tyrosine residues on
the intracellular OB-Rb (7, 11). In general, tyrosine
phosphorylation of cytokine and growth factor recep-
tors activates intracellular signals by recruiting spe-
cific signaling proteins with specialized phosphoty-
rosine-binding domains called SH2 domains. Thus the
two OB-Rb tyrosine residues that are phosphorylated
during receptor activation mediate distinct signaling
pathways, with SHP-2 binding to Tyr 985 positively
Fig. 6. Schematic representation of the signaling pathways of IL-6, leptin, and TNF-a and their interaction with
insulin signaling. JAK, Janus kinases; STAT, signal transducers and activators of transcription; SOCS-3,
suppressor of cytokine signaling-3; MAPK, mitogen-activated protein kinases; IR, insulin receptor; IRS, insulin
receptor substrates; PI3K, phosphatidylinositol 3-kinase; Akt, protein kinase B; ERK, extracellular factor-










regulating the extracellular factor-regulated kinase
(ERK)-c-fos pathway, and STAT3 binding to Tyr1138
mediating the inhibitory SOCS-3 pathway (7, 10, 11,
94). It has been shown that SOCS-3 is a leptin-regu-
lated inhibitor of proximal leptin signaling in vivo, and,
therefore, excessive SOCS-3 activity in leptin-respon-
sive cells is a potential mechanism for leptin resistance
(94).
Leptin is not only a central regulator of body fat
mass by decreasing food intake and increasing energy
expenditure, but it also could be involved in insulin
resistance induction, possibly via peripheral mecha-
nisms of action (44). Recent reports suggest complex
interactions between the leptin and insulin signaling
pathways that can potentially lead to differential mod-
ification of the metabolic effects of insulin exerted
through insulin receptor substrates (IRS-1 and IRS-2).
In fact, leptin can act through some components of the
insulin-signaling cascade, such as IRS-1 and IRS-2, PI
3-kinase, and MAPK, and can modify insulin-induced
changes in gene expression in vitro and in vivo (84,
159). It has been shown that, in Fao cells, leptin alone
has no effect on the insulin-signaling pathway, but
leptin pretreatment transiently enhances insulin-in-
duced tyrosine phosphorylation and PI 3-kinase bind-
ing to IRS-1 while producing an inhibition of tyrosine
phosphorylation and PI 3-kinase binding to IRS-2
(159). Leptin alone also induces serine phosphorylation
of Akt and glycogen synthase 3, but to a lesser extent
than insulin, and the combination of these hormones is
not additive. A divergence of leptin effects on insulin-
stimulated IRS-1 and IRS-2-mediated signaling and on
three downstream kinases suggests a complex and
multidimensional interaction between these two hor-
monal signaling systems. Leptin rapidly activates sig-
naling pathways directly at the level of insulin-sensi-
tive tissues through the OB-Rb, and these pathways
overlap with, but are distinct from, those engaged by
insulin (84).
TNF-a has been shown to induce a rapid release of
leptin from white adipose tissue (54, 85). Human stud-
ies have yielded conflicting results. Infusion of TNF-a
to patients was followed by a rapid rise in serum leptin
concentrations (198), whereas long-term exposure of
cultured human adipocytes to TNF-a resulted in a
reduction of leptin mRNA levels (50). Therefore, fur-
ther studies are needed to clarify the exact relationship
between TNF-a and leptin in the context of insulin
resistance.
It has recently been shown that, in the presence of
markedly reduced insulin action in skeletal muscle,
glucose is partly shunted to white adipose tissue (83).
Thus selective insulin resistance in muscle promotes
redistribution of substrates to adipose tissue, thereby
contributing to increased adiposity and development of
the prediabetic syndrome. In obese patients, increased
production of nonesterified fatty acids and cytokines
contributes to insulin resistance. The changes in sys-
temic metabolism that lead to insulin resistance have
been reported to develop in an attempt to prevent
further weight gain (32). Mobilization of energy stores,
impaired insulin signaling, increased lipolysis, and
central neuroendocrine effects, such as HPA activa-
tion, may be adaptive under certain circumstances,
including the early stages of fuel storage and in acute
inflammation, whereas such changes may become mal-
adaptive during sustained weight gain (111). In this
sense, IL-6 reduces LPL activity, reducing fuel storage
and thereby limiting weight gain on the one hand, but
IL-6 also increases hepatic synthesis of procoagulant
molecules, contributing to dyslipidemia on the other
hand.
The receptor complex mediating the biological activ-
ities of IL-6 consists of two distinct membrane-bound
glycoproteins, an 80-kDa cognate receptor (IL-6R) and
a 130-kDa signal-transducing element (gp130). Cellu-
lar activation by IL-6 requires binding to its cognate
receptor and the resulting dimerization of gp130 (77).
In addition to the membrane-bound receptor, the
IL-6Rs binds IL-6 with a similar affinity to that of the
cognate receptor and prolongs its plasma half-life. The
IL-6R/IL-6Rs complex is capable of activating cells via
interaction with membrane-bound gp130 (Fig. 6). This
feature makes the IL-6R/IL-6Rs complex an agonist for
cell types that, although they express gp130, would not
inherently respond to IL-6 alone (77). Hence, the
IL-6Rs has the ability to widen the repertoire of cell
types that are responsive to IL-6. Signaling is facili-
tated through the homodimerization of gp130 to the
ligand-receptor complex. This mediates phosphoryla-
tion of gp130-associated JAKs, which facilitates the
docking of STAT1/STAT3 factors to gp130 and their
phosphorylation. IL-6 also activates the Ras-Raf sig-
naling cascade, which regulates phosphorylation of
MAPK and ultimately activation of transcription fac-
tors such as CEBP (77).
CROSS TALK WITH NEUROENDOCRINE PATHWAYS
Adipose tissue is an endocrine organ influencing
many aspects of fuel metabolism through a network of
local and systemic signals that interact with the estab-
lished neuroendocrine regulators. Cytokine production
appears to be acutely regulated by sympathetic stimu-
lation. Catecholamines have been shown to regulate
the production of leptin, IL-6, and TNF-a (111). Iso-
prenaline infusions in humans had a stimulatory effect
on circulating IL-6 concentrations, but little or no ap-
preciable change was observed in TNF-a. Conversely,
catecholamines and synthetic adrenergic agonists have
been demonstrated to rapidly suppress leptin mRNA
levels in mouse adipocytes (166), whereas in humans,
isoprenaline produced an acute suppression of plasma
leptin concurrently with an increased lipolytic activity
(125).
It has been reported that IL-6 directly stimulates
adrenal cortisol release in addition to stimulating hy-
pothalamic CRH and pituitary ACTH release (72). Ad-
ipose tissue IL-6 may, therefore, act as a feedforward
regulator of HPA function. Cortisol suppression of ad-
ipose IL-6 production may serve as a feedback inhibitor










could be influenced by IL-6 originating from perirenal
adipose tissue surrounding the adrenal gland itself. In
humans, IL-6 administration has been shown to induce
a synchronized dose-dependent increase in resting
metabolic rate and HPA activity, suggesting that hy-
pothalamic CRH may mediate both of these functions
(167). In contrast to stimulating ACTH, cortisol, GH,
and prolactin release, IL-6 suppresses TSH secretion
in a dose-dependent manner. This finding provides
support to the participation of IL-6 and other inflam-
matory cytokines in generating the “euthyroid sick
syndrome” in acute illness (92). The acute effects of
IL-6 on GH, prolactin, and TSH release are also
thought to be mediated via actions on hypothalamic
control centers (108). Direct actions of IL-6 to modify
anterior pituitary hormone release are plausible but
unlikely, because they usually take more than 4–8 h to
appear, and they have been documented to begin after
1 h of peaking between 3 and 4 h (167). Moreover, how
circulating IL-6 reaches hypothalamic CRH and other
regulatory neurons remains unclear, given the exis-
tence of the protective blood-brain barrier. There may
be a special transport system for inflammatory cyto-
kines, or they may directly activate the terminals of
these neurons on the median eminence, which is out-
side the blood-brain barrier. Alternatively, IL-6 may
cause endothelial and glial cells to secrete other medi-
ators of inflammation, which reach the hypothalamic
neurons in a cascade-like fashion (126).
Interestingly, no appreciable changes in luteinizing
hormone (LH) and follicle-stimulating hormone release
in response to IL-6 administration have been observed
(167). This is in agreement with animal studies (108)
but contrasts with the inhibitory effects of IL-1 and
TNF-a on the pulsatile release of LH (130).
The studies looking at the relation between plasma
leptin and cortisol concentrations have yielded conflict-
ing results (111). Diurnal variations of leptin and cor-
tisol are inversely related, with leptin concentrations
peaking during the nadir of cortisol secretion (95).
Furthermore, physiological doses of leptin have been
shown to inhibit ACTH-stimulated cortisol production
in cultured cells (15). Leptin increases CRH expression
in the paraventricular nucleus. Thus leptin and the
HPA axis are reciprocally related, with interactions at
several levels. Glucocorticoids have been suggested to
exert a counterregulatory influence on leptin action,
with the HPA axis activity possibly setting a level of
target-organ sensitivity to leptin (190).
CONCLUDING REMARKS
Adipocyte triglyceride stores are continously turning
over at a rate that is tightly controlled by hormones.
The physiological, cellular, and molecular mechanisms
regulating the primary function of fat cells, to store
excess ingested energy as triglycerides and to release
fatty acids to meet the energy needs of other tissues,
have been rapidly unfolding in the past decades. Novel
metabolic functions of adipose tissue, apart from its
central role in triglyceride metabolism, have been un-
covered. In addition to the classical actions of insulin
and counterregulatory hormones on adipocyte metab-
olism, fat cells play an active role in modulating their
own metabolism, and hence their size, via autocrine
and paracrine mechanisms. Newly discovered roles
include the production of the cytokines IL-6, TNF-a,
and leptin, which play decisive roles in the develop-
ment of obesity and insulin resistance. The local pro-
duction of angiotensinogen may play an etiological role
in the development of obesity-related hypertension.
Furthermore, synthesis of estrogens by adipose tissue
may mediate effects of obesity on the risk for osteopo-
rosis and cancer. Thus the enlargement of the adipose
mass has pleiotropic effects on endocrine and metabolic
events at the whole body level that may contribute to
the pathogenesis of detrimental complications of obe-
sity.
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